KUALA LUMPUR: Genting Bhd, along with its partner TauRx Pharmaceuticals Ltd., is currently seeking approval from both the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) for its Alzheimer's disease drug.
Genting president, chief operating officer, and executive director Datuk Seri Tan Kong Han said Taurx has finished phase three trial and the open label trial.
"When we finish the clinical trials, we are committed to fulfilling our promise. It's important because receiving a placebo isn't fair to you.
"Our commitment is to provide the actual drug after the 18-month trial period, regardless of whether you initially received the drug or the placebo.
"The fact that most participants opted to continue in what we call the open-label phase suggests that something must be effective. People wouldn't stay involved for so long if it wasn't working," he said at the press conference.
Tan said the company has made considerable progress with the MHRA.